Library — CHDR

Search

Filter

Key publication (484)
Poster (20)
PhD Thesis (16)
Brochure (19)
Factsheet (4)
Annual report (6)

Optimizing the glutamatergic challenge model for psychosis, using S+ -ketamine to induce psychomimetic symptoms in healthy volunteers.

Kleinloog D, Uit den Boogaard A, Dahan A, Mooren R, Klaassen E, Stevens J, Freijer J, van Gerven J

Journal of psychopharmacology (Oxford, England), 2015 Mar; 29(4):401-13

View publication
The return of the prodigal son and the extraordinary development route of antibody TGN1412 - lessons for drug development and clinical pharmacology.

Kenter MJ, Cohen AF

British journal of clinical pharmacology, 2015 Mar; 79(4):545-7

View publication
The effects of the nonselective benzodiazepine lorazepam and the α2 /α3 subunit-selective GABAA receptor modulators AZD7325 and AZD6280 on plasma prolactin levels.

Te Beek ET, Chen X, Jacobs GE, Nahon KJ, de Kam ML, Lappalainen J, Cross AJ, van Gerven JM, Hay JL

Clinical pharmacology in drug development, 2015 Feb; 4(2):149-54

View publication
First proof of pharmacology in humans of a novel glucagon receptor antisense drug.

van Dongen MG, Geerts BF, Morgan ES, Brandt TA, de Kam ML, Romijn JA, Cohen AF, Bhanot S, Burggraaf J

Journal of clinical pharmacology, 2015 Feb; 55(3):298-306

View publication
Ketamine interactions with biomarkers of stress: a randomized placebo-controlled repeated measures resting-state fMRI and PCASL pilot study in healthy men.

Khalili-Mahani N, Niesters M, van Osch MJ, Oitzl M, Veer I, de Rooij M, van Gerven J, van Buchem MA, Beckmann CF, Rombouts SA, Dahan A

NeuroImage, 2015 Feb

View publication
Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics.

Heuberger JA, Guan Z, Oyetayo OO, Klumpers L, Morrison PD, Beumer TL, van Gerven JM, Cohen AF, Freijer J

Clinical pharmacokinetics, 2015 Jan; 54(2):209-19

View publication
AZD6280, a novel partial γ-aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers.

Chen X, Jacobs G, de Kam ML, Jaeger J, Lappalainen J, Maruff P, Smith MA, Cross AJ, Cohen A, van Gerven J

Journal of clinical psychopharmacology, 2015 Jan; 35(1):22-33

View publication
The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol.

Kleinloog D, Stevens J, Heuberger J, Spinhoven P, van Gerven J

Psychiatry research, 2014 Dec; 220(3):945-53

View publication
The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.

Chen X, Jacobs G, de Kam M, Jaeger J, Lappalainen J, Maruff P, Smith MA, Cross AJ, Cohen A, van Gerven J

British journal of clinical pharmacology, 2014 Nov; 78(6):1298-314

View publication

«
1
2
...
5
6
7
8
9
10
11
...
53
54
»